<DOC>
	<DOCNO>NCT00967343</DOCNO>
	<brief_summary>The purpose study determine whether administration donor lymphocyte preparation deplete functional host alloreactive T-cells ( ATIR ) T-cell depleted stem cell transplant relate , haploidentical donor enhances survival improve immune effect infection prevent graft-versus-host disease .</brief_summary>
	<brief_title>Efficacy Safety Donor Lymphocyte Preparation Depleted Functional Host Alloreactive T-cells ( ATIR ) Patients Undergoing Peripheral Blood Stem Cell Transplant From Related , Haploidentical Donor</brief_title>
	<detailed_description>Allogeneic stem cell transplantation treatment choice many patient leukemia hematologic malignancy . However , major limitation therapy significant number patient fully HLA-matched donor find . The application partially HLA-matched ( haploidentical ) family donor , virtually always available , complication . If T-cell add-back increase risk life-threatening infection disease relapse , case T-cell add-back risk graft-versus-host disease raise . Kiadis Pharma develop method selectively deplete host alloreactive T-cells photodynamic therapy , use TH9402 ex vivo . The donor lymphocyte preparation deplete functional host alloreactive T-cells ( ATIR ) administer patient 28-42 day stem cell transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>One follow hematological malignancy : Acute Myeloid Leukemia ( AML ) Acute Lymphoblastic Leukemia ( ALL ) Myelodysplastic Syndrome ( MDS ) Phpositive chronic myeloid leukemia ( CML ) NonHodgkin Lymphoma ( NHL ) Myelodysplastic Syndrome ( MDS ) Chronic Myeloid Leukemia ( CML ) Multiple Myeloma ( MM ) Chronic Lymphocytic Leukemia ( CLL ) Myeloproliferative Syndrome ( MPS ) AML 1st complete remission good risk karyotype MM feature concurrent extramedullar disease nonresponsive prior therapy CML blast crisis CLL concurrently transform highgrade lymphoma fail demonstrate least partial remission NHL concurrent bulky disease ( ≥ 5 cm ) Diffusing Capacity Carbon Monoxide ( DLCO ) &lt; 40 % predict Left ventricular ejection fraction &lt; 40 % AST/SGOT &gt; 2.5 x ULN Bilirubin &gt; 1.5 x ULN Creatinine &gt; 1.5 x ULN HIV positive Positive pregnancy test woman childbearing age Prior haploidentical peripheral blood stem cell cord blood transplantation Less 2 year prior allogeneic stem cell transplantation Estimated probability survive less three month Major anticipate illness organ failure incompatible survival transplant Severe psychiatric illness mental deficiency sufficiently severe make compliance transplant treatment unlikely informed consent impossible Known allergy component ATIR Any condition , opinion investigator , make patient ineligible study Donor Haploidentical family donor 2 3 mismatch HLAA , B and/or DR locus unshared haplotype . Male female , age ≥ 16 , ≤ 75 year . Donors must fit receive GCSF undergo apheresis ( normal blood count , normotensive history stroke ) . Donor must Eastern Cooperative Oncology Group ( ECOG ) performance status 2 less . Donor must provide write informed consent . Donor Medically uncontrolled coronary heart disease . Myocardial infarction within last 3 month . History uncontrolled seizure . History malignancy ( except basal cell squamous carcinoma skin , positive PAP smear subsequent negative follow ) . Positive test result mandatory viral test applicable region , except positive cytomegalovirus ( CMV ) result , lead exclusion . Presence transmissible disease ( HIV positive ) , major illness , suspect systemic dysfunction and/or active inflammatory autoimmune disorder . Female donor pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Haploidentical stem cell transplantation</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>Immune reconstitution</keyword>
	<keyword>Alloreactive T-cells</keyword>
	<keyword>Photodepletion</keyword>
	<keyword>TH9402</keyword>
	<keyword>Transplant related mortality</keyword>
	<keyword>Hematologic malignancy</keyword>
</DOC>